MERCK KGAA
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1668-01-01
- Employees
- 62.9K
- Market Cap
- $84.2B
- Website
- http://www.merckgroup.com/de
A Study Using Recombinant Human Chorionic Gonadotrophin (rhCG, Ovidrel®) in the Induction of Final Follicle Maturation and Early Luteinization in Chinese Women Undergoing in Vitro Fertilization and Embryo Transfer (IVF/ET)
Phase 3
Completed
- Conditions
- Infertility
- Interventions
- Drug: Urinary-hCGDrug: r-hCG
- First Posted Date
- 2010-03-05
- Last Posted Date
- 2014-07-31
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 218
- Registration Number
- NCT01081756
- Locations
- 🇨🇳
Peking University 3rd Hopistal, Beijing, China
To Evaluate the Convenience, Safety and Efficacy of Follitropin Alfa Liquid Pen Compared With Follitropin Beta Liquid Pen
Phase 3
Completed
- Conditions
- InfertilityOvulation Induction
- Interventions
- First Posted Date
- 2010-03-05
- Last Posted Date
- 2014-07-31
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 34
- Registration Number
- NCT01081639
A Study Using Micronised Progesterone (Crinone® 8%) in the Luteal Phase Support of Women Undergoing in Vitro Fertilisation (IVF) and Embryo Transfer (ET)
- First Posted Date
- 2010-03-05
- Last Posted Date
- 2014-07-31
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 238
- Registration Number
- NCT01081652
- Locations
- 🇨🇳
Peking University 3rd Hopistal, Beijing, China
An Observational Study to Compare the Dose of Gonal-fTM FbM Prescribed by the Doctor With the Recommendation of the Dose Calculator Consort and to Evaluate the Ease of Use of Pre-filled Pen of Gonal-fTM FbM Pen
Terminated
- Conditions
- Multifollicular Stimulation
- First Posted Date
- 2010-03-04
- Last Posted Date
- 2014-07-02
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 25
- Registration Number
- NCT01080729
- Locations
- 🇧🇪
ZNA Middelheim, Antwerpen, Lindendreef 1, Belgium
Rebif Compliance Support Program - Assessing Needs in Multiple Sclerosis
Completed
- Conditions
- Multiple Sclerosis
- First Posted Date
- 2010-03-04
- Last Posted Date
- 2014-07-31
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 1257
- Registration Number
- NCT01080573
- Locations
- 🇬🇧
Bupa Home Healthcare, Harlow, Essex, United Kingdom
Metabolic Endocrinology and Growth Hormone in Adults
Completed
- Conditions
- Adult Growth Hormone Deficiency
- First Posted Date
- 2010-03-04
- Last Posted Date
- 2014-03-11
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 90
- Registration Number
- NCT01080755
An Observational Study to Evaluate the Efficacy of Lodoz in a Population of Hypertensive Patients
Completed
- Conditions
- Hypertension
- First Posted Date
- 2010-03-04
- Last Posted Date
- 2014-08-05
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 1007
- Registration Number
- NCT01080742
- Locations
- 🇹🇭
Thammasat Heart Center, Thammasat University Hospital, Pathumthani, Thailand
An Active-controlled, Clinical Trial to Assess Central Hemodynamic Effects of Bisoprolol in Hypertensive Patients (Central Hemodynamic Assessment Measured in Patient With HypertensION [CHAMPION])
- First Posted Date
- 2010-03-03
- Last Posted Date
- 2014-02-13
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 209
- Registration Number
- NCT01079962
- Locations
- 🇰🇷
Severance Hosptial, 250, Seongsanno, Seodaemungu, Seoul, Korea, Republic of
A Phase II Study to Assess the Efficacy and Safety of Luveris® (Lutropin Alfa) in Mid Follicular Phase for Controlled Ovarian Stimulation (COS) in Advanced Reproductive Age
Phase 2
Terminated
- Conditions
- Ovulation InductionInfertility
- Interventions
- Drug: r-hLH + r-hFSHDrug: r-hFSHDrug: Recombinant Human Choriogonadotropin (r-hCG)
- First Posted Date
- 2010-03-03
- Last Posted Date
- 2014-02-27
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 93
- Registration Number
- NCT01079949
- Locations
- 🇪🇸
Instituto Marqués, Barcelona, Spain
Study of Therapeutic Options for Subjects Discontinuing Efalizumab and Experiencing Disease Recurrence
Phase 4
Completed
- Conditions
- Psoriasis
- Interventions
- Drug: CyclosporinsDrug: RetinoidsDrug: Systemic corticosteroidsDrug: Systemic corticosteroids/methotrexate
- First Posted Date
- 2010-03-03
- Last Posted Date
- 2014-02-27
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 41
- Registration Number
- NCT01079988
© Copyright 2025. All Rights Reserved by MedPath